Madurai News

The Global NASH Biomarker Market Assessed to Witness Growth at $3700.0 Million by 2028

 Breaking News
  • No posts were found

The Global NASH Biomarker Market Assessed to Witness Growth at $3700.0 Million by 2028

June 15
13:14 2021
The Global NASH Biomarker Market Assessed to Witness Growth at $3700.0 Million by 2028

Global non-alcoholic steatohepatitis (NASH) biomarker market
As per Triton’s report, the global non-alcoholic steatohepatitis (NASH) biomarker market attained $772.4 million in 2020, and is anticipated to progress at a CAGR of 21.28% by 2028.

A recent study by Triton Market Research titled ‘Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market’ entails the Global Analysis and Forecasts by Type (Hepatic fibrosis Biomarker, Oxidative stress Biomarker, Serum Biomarker, Apoptosis Biomarker, Other Types), Industry Verticals (Pharma & CRO Industry, Hospital, Diagnostic Lab, Academic Research Key), and Geography (Europe, Middle East and Africa, Latin America, Asia-Pacific, North America).

NASH is an advanced form of non-alcoholic fatty liver disease, and can develop into severe conditions, such as hepatocellular carcinoma and cirrhosis. A NASH biomarker is utilized by professionals in hospitals, CROs, or diagnostic labs.

 

Request Free Sample of the Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market Report @ https://www.tritonmarketresearch.com/reports/non-alcoholic-steatohepatitis-biomarker-market#request-free-sample

 

Triton’s research report suggests that the global non-alcoholic steatohepatitis (NASH) biomarker market is assessed to develop at a CAGR of 21.28% in revenue through the years 2021-2028. It is also likely to attain revenue worth $3700.0 million by 2028.

The rising prevalence of NASH, coupled with the growing occurrence of metabolic comorbidities, are stimulating the growth of the non-alcoholic steatohepatitis biomarker market over the forecast period. Non-alcoholic fatty liver disease is one of the leading causes of liver damage globally and leads to developing the severe condition known as NASH. Additionally, over the years, there has been a tremendous growth in the obesity rates across regions, which is likely to increase NASH’s prevalence among the global population. Hence, this rise in NAFLD and obesity rates is expected to supplement the studied market’s growth in the near future.

However, the side effects of NASH therapeutics and the unavailability of specialized diagnostic tests for NAFLD are major restraints that negatively impact the growth of the NASH biomarker market.

The market for NASH biomarker is divided into type and industry verticals. Based on type, the market is segmented into hepatic fibrosis biomarker, oxidative stress biomarker, serum biomarker, apoptosis biomarker, and other types. The industry verticals are branched into pharma & CRO industry, hospital, diagnostic lab, and academic research key.

North America is dominating the non-alcoholic steatohepatitis biomarker market globally. The region’s strong growth is primarily owing to the favorable reimbursement policies in the healthcare industry, along with the easy availability of new therapeutics. Further, the surge in occurrence of diabetes and obesity is adding to the growth of the studied market across the United States and Canada.

Genfit SA, Bristol Myers Squibb Company, Madrigal Pharmaceuticals, Gilead Sciences Inc, Siemens Healthineers, AstraZeneca, Zydus Cadila, Allergan, Viking Therapeutics, Novo Nordisk, Merck & Co, Pfizer Inc, and Novartis AG are major enterprises in the market.

 

Purchase this Report @ https://www.tritonmarketresearch.com/reports/non-alcoholic-steatohepatitis-biomarker-market#purchase-option

 

Question & Answer: Non-Alcoholic Steatohepatitis (NASH) Biomarker Market

Question 1: What major factors are stimulating the growth of the non-alcoholic steatohepatitis biomarker market?

Answer: The rising prevalence of NASH, coupled with the growing occurrence of metabolic comorbidities, are stimulating the growth of the non-alcoholic steatohepatitis biomarker market over the forecast period. Non-alcoholic fatty liver disease is one of the leading causes of liver damage globally and leads to developing the severe condition known as NASH. Additionally, over the years, there has been a tremendous growth in the obesity rates across regions, which is likely to increase NASH’s prevalence among the global population. Hence, this rise in NAFLD and obesity rates is expected to supplement the studied market’s growth in the near future.

Question 2: What major restraints negatively impact the growth of the NASH biomarker market?

Answer: The side effects of NASH therapeutics and the unavailability of specialized diagnostic tests for NAFLD are major restraints that negatively impact the growth of the NASH biomarker market.

Question 3: Which region is dominating the non-alcoholic steatohepatitis biomarker market?

Answer:  North America is dominating the non-alcoholic steatohepatitis biomarker market globally. The region’s strong growth is primarily owing to the favorable reimbursement policies in the healthcare industry, along with the easy availability of new therapeutics. Further, the surge in occurrence of diabetes and obesity is adding to the growth of the studied market across the United States and Canada.

Question 4: Which are the major enterprises in the NASH biomarker market.?

Answer: Genfit SA, Bristol Myers Squibb Company, Madrigal Pharmaceuticals, Gilead Sciences Inc, Siemens Healthineers, AstraZeneca, Zydus Cadila, Allergan, Viking Therapeutics, Novo Nordisk, Merck & Co, Pfizer Inc, and Novartis AG are major enterprises in the market.

 

Related Report:

Global Bariatric Surgery Market

The global bariatric surgery market is estimated to grow at a CAGR of 9.41% during the estimated period of 2019-2028, while attaining $4913.1 million in revenue by 2028.

Bariatric surgery, also known as weight loss surgery, is one of the major procedures for treating obesity. It is generally the last option preferred by patients after incorporating other weight loss methods.

The rising prevalence of diabetes and cardiac diseases, along with growing obesity rates, are stimulating the growth of the studied market over the forecast period. Additionally, the technological advancements and surge in government initiatives relating to obesity are opening new avenues for the market to reach its anticipated growth.

However, the high cost of bariatric surgeries and lack of awareness among patients hamper the overall development of the global market.

 

About Us:

We are a leading market research company with offices in the UK, providing the best online market research and data search reports to our clients.

Media Contact
Company Name: Triton Market Research
Contact Person: Matt Dixson
Email: Send Email
Phone: +44 7441 911839
Address:196, wards wharf approach London E16 2EQ
Country: United Kingdom
Website: https://www.tritonmarketresearch.com/

Categories